Telix Pharmaceuticals Ltd
Company Profile
Business description
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Contact
55 Flemington Road
Level 4, North Melbourne
MelbourneVIC3051
AUST: +61 390933855
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,184
Telix Pharmaceuticals Ltd News & Analysis
stocks
What did Morningstar subscribers buy and sell in April?
stocks
Revenue growth on track for undervalued ASX healthcare stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,692.80 | 143.80 | -1.63% |
| CAC 40 | 7,927.75 | 152.99 | -1.89% |
| DAX 40 | 24,802.78 | 661.03 | -2.60% |
| Dow JONES (US) | 48,147.33 | 949.73 | -1.93% |
| FTSE 100 | 10,346.34 | 106.34 | -1.02% |
| HKSE | 22,410.80 | 430.82 | -1.89% |
| NASDAQ | 22,617.73 | 1,261.47 | -5.28% |
| Nikkei 225 | 56,436.65 | 3,007.56 | -5.06% |
| NZX 50 Index | 14,107.41 | 139.84 | -0.98% |
| S&P 500 | 6,910.39 | 265.44 | -3.70% |
| S&P/ASX 200 | 8,592.60 | 137.80 | -1.58% |
| SSE Composite Index | 3,533.79 | 43.82 | -1.22% |